UK green light for Roche’s purchase of Spark
The Competition and Markets Authority has unconditionally approved the deal
Read Moreby Selina McKee | Dec 16, 2019 | News | 0
The Competition and Markets Authority has unconditionally approved the deal
Read Moreby Selina McKee | Nov 25, 2018 | News | 0
Novartis’ Luxturna has been approved by regulators in Europe to treat a rare inherited condition that causes sight loss.
Read Moreby Selina McKee | Jul 17, 2018 | News | 0
Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B.
Read Moreby Selina McKee | Jan 25, 2018 | News | 0
Novartis has bought itself rights to Spark Therapeutic’s gene therapy for a certain type of vision loss, in a deal worth up to $170 million.
Read Moreby Selina McKee | Dec 20, 2017 | News | 0
Spark Therapeutics’ Luxturna has become the first gene therapy ever to be approved by the US Food and Drug Administration for an inherited condition.
Read Moreby Selina McKee | Jul 22, 2016 | News | 0
Pfizer and Spark Therapeutics say their investigational haemophilia B drug SPK-9001 has been awarded breakthrough therapy status by the US Food and Drug Administration.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479